CA2948178A1 - Anti-viral compounds, pharmaceutical compositions, and methods of use thereof - Google Patents
Anti-viral compounds, pharmaceutical compositions, and methods of use thereof Download PDFInfo
- Publication number
- CA2948178A1 CA2948178A1 CA2948178A CA2948178A CA2948178A1 CA 2948178 A1 CA2948178 A1 CA 2948178A1 CA 2948178 A CA2948178 A CA 2948178A CA 2948178 A CA2948178 A CA 2948178A CA 2948178 A1 CA2948178 A1 CA 2948178A1
- Authority
- CA
- Canada
- Prior art keywords
- virus
- compound
- optionally substituted
- formula
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 CCC*CCC(C)=NCC* Chemical compound CCC*CCC(C)=NCC* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461991418P | 2014-05-09 | 2014-05-09 | |
| US61/991,418 | 2014-05-09 | ||
| US201562177900P | 2015-03-25 | 2015-03-25 | |
| US62/177,900 | 2015-03-25 | ||
| PCT/US2015/030014 WO2015172099A1 (en) | 2014-05-09 | 2015-05-08 | Anti-viral compounds, pharmaceutical compositions, and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2948178A1 true CA2948178A1 (en) | 2015-11-12 |
Family
ID=54393071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2948178A Abandoned CA2948178A1 (en) | 2014-05-09 | 2015-05-08 | Anti-viral compounds, pharmaceutical compositions, and methods of use thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9884876B2 (enExample) |
| EP (1) | EP3139920A4 (enExample) |
| JP (1) | JP6419313B2 (enExample) |
| CN (1) | CN106456615B (enExample) |
| AU (3) | AU2015255714B2 (enExample) |
| CA (1) | CA2948178A1 (enExample) |
| MX (2) | MX2016014642A (enExample) |
| TW (1) | TW201623265A (enExample) |
| WO (1) | WO2015172099A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019021520A2 (pt) | 2017-04-14 | 2020-08-04 | Tollnine, Inc. | oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune |
| CA3051422A1 (en) * | 2018-08-09 | 2020-02-09 | Kineta, Inc. | Activators of the retinoic acid inducible gene "rig-i" pathway and methods of use thereof |
| TW202035426A (zh) * | 2018-08-17 | 2020-10-01 | 美商奇尼塔公司 | 視黃酸誘導基因"rig-i"途徑之活化劑及其使用方法 |
| US20220009945A1 (en) * | 2018-11-02 | 2022-01-13 | Aicuris Gmbh & Co. Kg | Novel urea 6,7-dihydro-4h-thiazole[5,4-c]pyridines active against the hepatitis b virus (hbv) |
| AU2020289560A1 (en) | 2019-06-05 | 2021-12-23 | Emory University | Peptidomimetics for the treatment of coronavirus and picornavirus infections |
| US20220273689A1 (en) * | 2019-07-09 | 2022-09-01 | Regents Of The University Of Minnesota | Potentiation of antiviral nucleobases as rna virus therapy |
| JP2022550454A (ja) * | 2019-10-02 | 2022-12-01 | ユニバーシティ オブ ワシントン | Ｂ型肝炎ウイルス感染の治療のための組成物及び方法 |
| IL295759A (en) | 2020-02-28 | 2022-10-01 | Tallac Therapeutics Inc | Transglutaminase mediated coupling |
| BR112022020020A2 (pt) | 2020-04-04 | 2022-11-22 | Pfizer | Métodos de tratamento da doença do coronavírus 2019 |
| MX2021013934A (es) | 2020-04-05 | 2021-12-15 | Pfizer | Compuestos y metodos para el tratamiento de covid-19. |
| US12485157B2 (en) | 2020-04-05 | 2025-12-02 | Pfizer Inc. | Method of treating COVID-19 |
| US12358897B2 (en) | 2020-04-05 | 2025-07-15 | Pfizer Inc. | Compounds and method of treating COVID-19 |
| CA3176626A1 (en) | 2020-05-08 | 2021-11-11 | David Dornan | Elastase-substrate, peptide linker immunoconjugates, and uses thereof |
| MX2022014505A (es) | 2020-05-19 | 2022-12-13 | Kallyope Inc | Activadores de la ampk. |
| CN113831301B (zh) * | 2020-06-08 | 2023-06-06 | 沈阳药科大学 | 苯并噻唑类衍生物及其用途 |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
| EP4178955A1 (en) | 2020-07-11 | 2023-05-17 | Pfizer Inc. | Antiviral heteroaryl ketone derivatives |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| EP4228631B1 (en) * | 2020-10-15 | 2024-08-21 | Baden-Württemberg Stiftung gGmbH | Flavi-block: a pan-flavivirus inhibitor |
| WO2022180003A1 (en) * | 2021-02-24 | 2022-09-01 | F. Hoffmann-La Roche Ag | Benzothiazolyl bicyclo[1.1.1]pentane derivatives for the treatment and prophylaxis of hepatitis b virus infection |
| WO2022204431A1 (en) * | 2021-03-24 | 2022-09-29 | Anavex Life Sciences Corp. | Prevention and treatment of coronavirus infection |
| US20250304559A1 (en) | 2021-03-30 | 2025-10-02 | Pfizer Inc. | Ether-Linked Antiviral Compounds |
| TWI869780B (zh) | 2022-03-02 | 2025-01-11 | 美商輝瑞大藥廠 | 用於篩檢人類個體之呼吸疾病、監測人類個體之呼吸病況以及提供決策支援之方法及電腦化系統 |
| WO2024149990A1 (en) | 2023-01-10 | 2024-07-18 | Oxford University Innovation Limited | Nirmatrelvir analogs as 3c like protease inhibitors for treating viral infections |
| CN121311467A (zh) | 2023-06-09 | 2026-01-09 | 辉瑞大药厂 | N-(甲氧羰基)-3-甲基-l-缬氨酰基-(4r)-n-{(1s)-1-氰基-2-[(3s)-2-氧代吡咯烷-3-基]乙基}-4-(三氟甲基)-l-脯氨酰胺及其溶剂化物的固体形式 |
| WO2025037206A1 (en) | 2023-08-11 | 2025-02-20 | Pfizer Inc. | Deuterated antiviral compounds |
| WO2025040743A1 (en) | 2023-08-22 | 2025-02-27 | Univerza V Ljubljani | Conjugated tlr7 and rig-i agonists |
| WO2025191272A1 (en) | 2024-03-13 | 2025-09-18 | Storm Therapeutics Ltd | Inhibitory compounds |
| CN119707862B (zh) * | 2025-02-24 | 2025-06-27 | 北京悦康科创医药科技股份有限公司 | 基于RLRs受体激动剂的疫苗佐剂脂质化合物、包含其的组合物及用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1024316A (en) * | 1911-07-29 | 1912-04-23 | Singer Mfg Co | Strip folding and guiding attachment for sewing-machines. |
| JPS53129036A (en) * | 1977-04-18 | 1978-11-10 | Fuji Photo Film Co Ltd | Color photographic material |
| JPH0780355B2 (ja) * | 1987-01-22 | 1995-08-30 | 富士写真フイルム株式会社 | 光学的情報記録媒体 |
| GB9923710D0 (en) * | 1999-10-08 | 1999-12-08 | Proteus Molecular Design | Chemical compounds |
| WO2004078115A2 (en) * | 2003-02-28 | 2004-09-16 | Viropharma, Incorporated | Benzothiazole compounds, compositions and methods for treatment and prophylaxis of rotavirus infections and associated diseases |
| US20050130974A1 (en) * | 2003-10-17 | 2005-06-16 | Rigel Pharmaceuticals, Inc. | Benzothiazole compositions and their use as ubiquitin ligase inhibitors |
| CN101925300A (zh) * | 2007-11-21 | 2010-12-22 | 雅培制药有限公司 | 作为大麻素受体配体的新化合物和其用途 |
| JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
| WO2012155352A1 (en) * | 2011-05-19 | 2012-11-22 | Eli Lilly And Company | Dihydroisoxazole compounds, parasiticidal uses and formulations thereof |
| AU2012315953A1 (en) * | 2011-09-30 | 2014-04-03 | Kineta, Inc. | Anti-viral compounds |
| US9073946B2 (en) * | 2013-01-15 | 2015-07-07 | Kineta, Inc. | Anti-viral compounds |
| CN103193770B (zh) * | 2013-03-20 | 2015-10-28 | 中国人民解放军第二军医大学 | 取代苯并噻唑类抗真菌化合物及其制备方法与应用 |
-
2015
- 2015-05-08 US US15/308,058 patent/US9884876B2/en not_active Expired - Fee Related
- 2015-05-08 TW TW104114809A patent/TW201623265A/zh unknown
- 2015-05-08 CN CN201580024136.9A patent/CN106456615B/zh not_active Expired - Fee Related
- 2015-05-08 MX MX2016014642A patent/MX2016014642A/es unknown
- 2015-05-08 EP EP15789075.7A patent/EP3139920A4/en not_active Withdrawn
- 2015-05-08 AU AU2015255714A patent/AU2015255714B2/en not_active Ceased
- 2015-05-08 JP JP2017511565A patent/JP6419313B2/ja not_active Expired - Fee Related
- 2015-05-08 CA CA2948178A patent/CA2948178A1/en not_active Abandoned
- 2015-05-08 WO PCT/US2015/030014 patent/WO2015172099A1/en not_active Ceased
-
2016
- 2016-11-08 MX MX2020005187A patent/MX2020005187A/es unknown
-
2018
- 2018-01-31 US US15/885,333 patent/US20190002477A1/en not_active Abandoned
-
2020
- 2020-03-12 AU AU2020201815A patent/AU2020201815A1/en not_active Abandoned
- 2020-05-08 US US16/870,208 patent/US20200270274A1/en not_active Abandoned
- 2020-06-29 AU AU2020204324A patent/AU2020204324A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW201623265A (zh) | 2016-07-01 |
| EP3139920A1 (en) | 2017-03-15 |
| JP6419313B2 (ja) | 2018-11-07 |
| US9884876B2 (en) | 2018-02-06 |
| CN106456615B (zh) | 2020-10-27 |
| AU2020201815A1 (en) | 2020-04-02 |
| AU2015255714A1 (en) | 2016-10-20 |
| US20170057978A1 (en) | 2017-03-02 |
| AU2020204324A1 (en) | 2020-07-16 |
| WO2015172099A1 (en) | 2015-11-12 |
| MX2020005187A (es) | 2020-08-20 |
| US20190002477A1 (en) | 2019-01-03 |
| US20200270274A1 (en) | 2020-08-27 |
| MX2016014642A (es) | 2017-05-25 |
| JP2017515901A (ja) | 2017-06-15 |
| EP3139920A4 (en) | 2017-11-01 |
| CN106456615A (zh) | 2017-02-22 |
| AU2015255714B2 (en) | 2019-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200270274A1 (en) | Anti-viral compounds, pharmaceutical compositions, and methods of use thereof | |
| US20160102099A1 (en) | Anti-viral compounds | |
| US20160122312A1 (en) | Anti-viral compounds, pharmaceutical compositions and methods of use thereof | |
| AU2017254812B2 (en) | Anti-viral compounds | |
| WO2016073947A1 (en) | Anti-viral compounds, pharmaceutical compositions, and methods of use thereof | |
| US20150342932A1 (en) | Anti-viral compounds | |
| WO2016057518A1 (en) | Anti-viral compounds, pharmaceutical compositions, and methods of use thereof | |
| OA19256A (en) | Anti-Viral Compounds. | |
| HK1199029B (en) | Anti-viral compounds | |
| NZ622636B2 (en) | Substituted benzothiazole compounds and their use in the treatment of viral infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200427 |
|
| FZDE | Discontinued |
Effective date: 20220913 |